お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:開放隅角緑内障:世界の治験動向
市場調査レポート
商品コード
246387

開放隅角緑内障:世界の治験動向

Open-Angle Glaucoma Global Clinical Trials Review, H1, 2020

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
開放隅角緑内障:世界の治験動向
出版日: 2020年01月13日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、開放隅角緑内障に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7およびE7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域
    • 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数:開放隅角緑内障治験件数の眼科治験件数に対する比率

フェーズ(相)別治験件数:G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:開放隅角緑内障治験件数の眼科治験件数に対する比率

フェーズ(相)別治験件数:E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - 開放隅角緑内障治療薬

有望な薬剤

  • 最新治験ニュース:開放隅角緑内障

治験プロファイルの基本情報

付録

図表

図表

List of Tables

  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials by Region, 2020*
  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2020*
  • Proportion of Open-Angle Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2020*
  • Open-Angle Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Open-Angle Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Open-Angle Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2020*
  • Open-Angle Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Open-Angle Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Open-Angle Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Open-Angle Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*

List of Figures

  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials by Region, 2020*
  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Open-Angle Glaucoma Therapeutics, Global, Clinical Trials I
目次
Product Code: GDHC6042CTIDB

GlobalData's clinical trial report, "Open-Angle Glaucoma Global Clinical Trials Review, H1, 2020" provides an overview of Open-Angle Glaucoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Open-Angle Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Open-Angle Glaucoma to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Open-Angle Glaucoma to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Open-Angle Glaucoma Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Open-Angle Glaucoma
  • Nov 06, 2019: Aerie's netarsudil shows promise in Phase II trial in Japan
  • Oct 22, 2019: Nicox reports positive results of secondary analyses from phase 2 trial further highlighting potential of NCX 470 in Glaucoma
  • Oct 15, 2019: Sun Ophthalmics to present updated XELPROS data at AAOPT/WCO 2019
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.